What You Should Know:
- Accenture has made a strategic investment, through Accenture Ventures, in 1910 Genetics, a biotechnology company revolutionizing drug discovery with its AI-powered platform. Terms of the investment were not disclosed.
- The strategic collaboration will combine Accenture's expertise in scaling AI solutions with 1910 Genetics' innovative technology to help biopharmaceutical companies accelerate drug development, reduce costs, and deliver more effective therapies
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
Gilead Sciences and Genesis Therapeutics Partner on AI-Driven Drug Discovery
What You Should Know:
- Gilead Sciences, a global biopharmaceutical company, and Genesis Therapeutics, an AI-focused biotechnology firm, have announced a strategic collaboration to discover and develop innovative small molecule therapies.
- The startegic partnership leverages Genesis' cutting-edge AI platform, GEMS, to accelerate drug discovery and development.
A Powerful Collaboration
Genesis Therapeutics' GEMS platform utilizes advanced AI techniques to generate and
Read More
The Role of AI in Streamlining Drug Discovery and Clinical Trials: A New Era in Pharmaceutical Innovation
In the rapidly evolving world of pharmaceuticals, artificial intelligence (AI) is emerging as a game-changer. From accelerating drug discovery to enhancing the efficiency of clinical trials, AI is revolutionizing how new medicines are brought to market. This transformation is not just limited to the research and development phases; AI is also playing a critical role in ensuring that drugs meet regulatory standards.
The AI Revolution in Drug Discovery
Drug discovery has traditionally been a
Read More
Quantiphi Invests in Transcell to Advance AI-Driven Drug Discovery
What You Should Know:
- Quantiphi, an AI-first digital engineering company, announced a strategic minority investment in Transcell, a pioneering stem cell-based biotech innovator. This collaboration marks a significant step forward in the integration of AI and biotechnology for drug discovery and development.
- By combining Quantiphi’s AI expertise with Transcell’s stem cell technology, the partnership aims to accelerate the development of innovative treatments while reducing
Read More
Absci and MSK Collaborate on Generative AI Drug Discovery
What You Should Know:
- Absci Corporation, a leader in generative AI drug creation, today announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop up to six novel cancer therapeutics.
- By combining Absci’s AI platform with MSK’s renowned cancer research expertise, the partnership aims to accelerate the discovery and development of new treatments for this devastating disease.
Absci's Integrated Drug Creation Platform
Absci's Integrated
Read More
Genomics plc Expands Drug Discovery Collaboration with Vertex
What You Should Know:
-Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company’s collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX) to use human genetics and machine learning to improve the discovery and development of new precision medicines.
-The partnership, which began in 2018, was previously extended in 2021. The collaboration will now run until 2026.
Vertex and
Read More
Athos Therapeutics Taps Vultr Cloud GPU to Power AI Drug Discovery Engine
What You Should Know:
- Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and inference.
- Powered by NVIDIA HGX H100 systems and running on Dell
Read More
Helix Launches Clinico-Genomic Datasets to Accelerate Precision Medicine Drug Discovery
What You Should Know:
- Helix, a leader in population genomics, is launching new datasets designed to empower life science companies in developing precision medicine therapies.
- These comprehensive datasets, built through collaborations with various health systems, provide researchers with a rich resource for drug discovery and development across multiple disease areas.
Unveiling the Power of Clinico-Genomic Data
The datasets offer a unique combination of longitudinal
Read More
Weave Bio Launches for AI-Powered Drug Development, Secures $10M
What You Should Know:
- Weave Bio, an AI-native life sciences platform company, announced today the public release of its flagship offering, AutoIND, and $10 million in seed funding co-led by Innovation Endeavors and Magnetic Ventures.
- AutoIND marks a significant advancement in drug development by automating and accelerating the preparation, writing, and review process for Investigational New Drug (IND) applications.
Automating the IND Process: A Game-Changer for Drug
Read More
Sanofi, Formation Bio, OpenAI Partner on AI-Powered Drug Discovery
What You Should Know:
- Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.
- Sanofi, Formation Bio, and OpenAI believe this collaboration will be
Read More
